{"id":"adenosine-phosphate","rwe":[],"tags":[{"label":"Adenosine Receptor Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Proto-oncogene tyrosine-protein kinase Src","category":"target"},{"label":"SRC","category":"gene"},{"label":"FBP1","category":"gene"},{"label":"DNPH1","category":"gene"},{"label":"Active","category":"status"},{"label":"Cystic fibrosis of the lung","category":"indication"},{"label":"Analgesics","category":"pharmacology"},{"label":"Anti-Arrhythmia Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Purinergic Agonists","category":"pharmacology"},{"label":"Purinergic P1 Receptor Agonists","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":58.761,"date":"","count":12,"signal":"Drug hypersensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=59)"}],"commonSideEffects":[],"contraindications":["Bronchiectasis"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T12:59:50.569140","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ADENOSINE PHOSPHATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:19:43.143613+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Adenosine Phosphate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:19:51.181711+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T23:19:57.914593+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:19:49.036064+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ADENOSINE PHOSPHATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:19:49.470493+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1775011/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:19:50.832521+00:00"}},"allNames":"adenovite","offLabel":[],"synonyms":["adenosine phosphate","adenosine 5'-phosphate","adenovite","5'-Adenylic acid","adenylic acid","phosphentaside","adenosine 5'-monophosphate","AMP","adenosine monophosphate"],"timeline":[],"aiSummary":"Adenovite, a marketed drug by an unspecified company, activates adenosine receptors to treat cystic fibrosis of the lung. Its key strength lies in its mechanism of reducing inflammation and slowing disease progression, setting it apart in the treatment landscape. The primary risk is the competition from disulfiram, an off-patent drug with the same target, which may limit Adenovite's market share.","brandName":"Adenovite","ecosystem":[{"indication":"Cystic fibrosis of the lung","otherDrugs":[{"name":"acetylcysteine","slug":"acetylcysteine","company":"Apothecon"},{"name":"cysteine","slug":"cysteine","company":"Hospira"},{"name":"ivacaftor","slug":"ivacaftor","company":"Vertex Pharms"},{"name":"lumacaftor","slug":"lumacaftor","company":"Vertex Pharms Inc"}],"globalPrevalence":890552}],"mechanism":{"target":"Proto-oncogene tyrosine-protein kinase Src","targets":[{"gene":"SRC","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase Src","protein":"Proto-oncogene tyrosine-protein kinase Src"},{"gene":"FBP1","source":"DrugCentral","target":"Fructose-1,6-bisphosphatase 1","protein":"Fructose-1,6-bisphosphatase 1"},{"gene":"DNPH1","source":"DrugCentral","target":"2'-deoxynucleoside 5'-phosphate N-hydrolase 1","protein":"2'-deoxynucleoside 5'-phosphate N-hydrolase 1"},{"gene":"TRPM4","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily M member 4","protein":"Transient receptor potential cation channel subfamily M member 4"},{"gene":"TRPM2","source":"DrugCentral","target":"Transient receptor potential cation channel subfamily M member 2","protein":"Transient receptor potential cation channel subfamily M member 2"},{"gene":"LDHA","source":"DrugCentral","target":"L-lactate dehydrogenase A chain","protein":"L-lactate dehydrogenase A chain"}],"moaClass":"Adenosine Receptor Agonists","modality":"Small Molecule","drugClass":"Adenosine Receptor Agonist","explanation":"","oneSentence":"","technicalDetail":"Adenovite acts as an agonist at adenosine receptors, specifically A1 and A2A subtypes, which can lead to the inhibition of proto-oncogene tyrosine-protein kinase Src, a key enzyme involved in the progression of cystic fibrosis."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Adenosine_monophosphate","title":"Adenosine monophosphate","extract":"Adenosine monophosphate (AMP), also known as 5'-adenylic acid, is a nucleotide. AMP consists of a phosphate group, the sugar ribose, and the nucleobase adenine. It is an ester of phosphoric acid and the nucleoside adenosine. As a substituent it takes the form of the prefix adenylyl-."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/92","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=ADENOSINE%20PHOSPHATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ADENOSINE PHOSPHATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Adenosine_monophosphate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:28:23.082968","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:19:57.914670+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"disulfiram","drugSlug":"disulfiram","fdaApproval":"1951-08-28","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"adenosine phosphate","indications":{"approved":[{"name":"Cystic fibrosis of the lung","source":"DrugCentral","snomedId":86555001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":890552,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (ORPHANET)"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(202)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"disulfiram","brandName":"disulfiram","genericName":"disulfiram","approvalYear":"1951","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07175441","phase":"PHASE2","title":"Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2026-04","conditions":["Advanced Unresectable Hepatocellular Carcinoma"],"enrollment":220,"completionDate":"2027-08"},{"nctId":"NCT07475546","phase":"PHASE3","title":"Combination Gerotherapeutic Interventions for Healthspan Improvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgelessRx","startDate":"2025-07-23","conditions":["Healthspan Improvement","Aging","Longevity"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":["AML","ALL","MDS","MPD Withou Myelofibrosis","NHL or HL","Inherited Metabolic Disorders","Hemoglobinopathies","Bone Marrow Failure","HLH"],"enrollment":31,"completionDate":"2026-12-20"},{"nctId":"NCT06579209","phase":"NA","title":"NAD+ Oral Supplement Pilot Intervention in Adult Females","status":"COMPLETED","sponsor":"University of Rhode Island","startDate":"2024-12-01","conditions":["Cognitive Change","Inflammation","Neurodegenerative Diseases"],"enrollment":53,"completionDate":"2026-02-20"},{"nctId":"NCT05494580","phase":"PHASE1,PHASE2","title":"Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-09-22","conditions":["Ovarian Cancer","Ovarian Carcinoma","Platinum-resistant Ovarian Cancer","Fallopian Tube Carcinosarcoma","Primary Peritoneal Cancer"],"enrollment":29,"completionDate":"2026-01-31"},{"nctId":"NCT02425904","phase":"PHASE2","title":"Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-05","conditions":["Langerhans Cell Histiocytosis"],"enrollment":25,"completionDate":"2026-07-30"},{"nctId":"NCT04708054","phase":"PHASE2,PHASE3","title":"Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-21","conditions":["Acute Myeloid Leukemia","Chronic Myelomonocytic Leukemia","Myelodysplastic Syndrome"],"enrollment":324,"completionDate":"2027-12-31"},{"nctId":"NCT07412821","phase":"PHASE1","title":"A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.","status":"NOT_YET_RECRUITING","sponsor":"Cure ADSSL1","startDate":"2026-03-21","conditions":["Denylosuccinate Synthetase-like 1-related Distal Myopathy"],"enrollment":2,"completionDate":"2027-12-31"},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":["Recurrent Acute Lymphoblastic Leukemia","Recurrent Adult Lymphoblastic Lymphoma","Recurrent Burkitt Leukemia","Recurrent Burkitt Lymphoma","Recurrent Childhood Lymphoblastic Lymphoma","Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Acute Lymphoblastic Leukemia","Refractory Burkitt Leukemia","Refractory Burkitt Lymphoma","Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Refractory Lymphoblastic Lymphoma"],"enrollment":42,"completionDate":"2027-08-01"},{"nctId":"NCT05105308","phase":"NA","title":"Chompions! A Treatment Study for Childhood Avoidant/Restrictive Food Intake Disorder (ARFID)","status":"COMPLETED","sponsor":"Duke University","startDate":"2022-02-10","conditions":["ARFID","Picky Eating","Eating Disorders in Children"],"enrollment":203,"completionDate":"2025-09-29"},{"nctId":"NCT02391519","phase":"","title":"Effects of High Altitude on AMPK Activation","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2016-01","conditions":["Pregnancy","IUGR","Preeclampsia"],"enrollment":84,"completionDate":"2026-12-31"},{"nctId":"NCT05917405","phase":"PHASE2","title":"Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2023-09-14","conditions":["Acute Myeloid Leukemia in Remission"],"enrollment":302,"completionDate":"2028-09-14"},{"nctId":"NCT06252870","phase":"PHASE2","title":"Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-07-18","conditions":["Graft Versus Host Disease","Hematologic Malignancy"],"enrollment":82,"completionDate":"2028-07-18"},{"nctId":"NCT04994808","phase":"PHASE2","title":"Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-08-11","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":23,"completionDate":"2026-07-16"},{"nctId":"NCT07328100","phase":"NA","title":"Efficacy and Safety of Coenzyme I for Injection on Vascular Aging.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2026-01-16","conditions":["Vascular Aging","NAD"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT06824064","phase":"PHASE2","title":"Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer","status":"RECRUITING","sponsor":"Riboscience, LLC.","startDate":"2025-01-17","conditions":["Metastatic Colorectal Cancer","Advanced Colorectal Cancer"],"enrollment":150,"completionDate":"2027-12"},{"nctId":"NCT07296354","phase":"PHASE4","title":"Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy","status":"NOT_YET_RECRUITING","sponsor":"Egyptian International Pharmaceutical Industries Co","startDate":"2026-01-10","conditions":["Neuropathic Pain"],"enrollment":200,"completionDate":"2029-01-10"},{"nctId":"NCT03119818","phase":"NA","title":"Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-06-14","conditions":["End-Stage Renal Disease (ESRD)"],"enrollment":11,"completionDate":"2017-07-29"},{"nctId":"NCT03117751","phase":"PHASE2,PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":["Acute Lymphoblastic Leukemia","Acute Lymphoblastic Lymphoma"],"enrollment":790,"completionDate":"2028-09-30"},{"nctId":"NCT07173088","phase":"NA","title":"Efficacy and Clinical Feasibility of the Ankle Muscle Power (AMP) Program for Return to Duty After an Ankle Fracture","status":"RECRUITING","sponsor":"Brian W. Noehren","startDate":"2025-11-13","conditions":["Ankle Fractures"],"enrollment":60,"completionDate":"2028-03"},{"nctId":"NCT02211755","phase":"PHASE1","title":"Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-06","conditions":["Neoplasms","Myelodysplastic Syndromes","Lymphomas"],"enrollment":28,"completionDate":"2025-08-15"},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":["B Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","Central Nervous System Leukemia","Testicular Leukemia"],"enrollment":5949,"completionDate":"2026-10-03"},{"nctId":"NCT03109080","phase":"PHASE1","title":"Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2017-07-24","conditions":["Breast Neoplasms, Triple-Negative","Breast Neoplasm Malignant Female","Radiotherapy Side Effect"],"enrollment":24,"completionDate":"2021-11-29"},{"nctId":"NCT01885689","phase":"PHASE2","title":"Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-02-10","conditions":["Adult Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Adult Acute Myeloid Leukemia in Remission","Myelodysplastic Syndrome","Secondary Myelodysplastic Syndrome","Chronic Myelomonocytic Leukemia","Therapy-Related Myelodysplastic Syndrome"],"enrollment":72,"completionDate":"2026-09-21"},{"nctId":"NCT02727803","phase":"PHASE2","title":"Personalized NK Cell Therapy in CBT","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-05-19","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Biphenotypic Leukemia","Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia With Myelodysplasia-Related Changes","Acute Myeloid Leukemia With Variant MLL Translocations","B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Chemotherapy-Related Leukemia","Chronic Myelomonocytic Leukemia","Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","ISS Stage II Plasma Cell Myeloma","ISS Stage III Plasma Cell Myeloma","Myelodysplastic Syndrome","Myelodysplastic Syndrome With Excess Blasts","Myelodysplastic Syndrome With Gene Mutation","Myelodysplastic/Myeloproliferative Neoplasm","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Myeloid Leukemia","Recurrent Adult Acute Myeloid Leukemia","Recurrent Hodgkin Lymphoma","Recurrent Non-Hodgkin Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Adult Acute Lymphoblastic Leukemia","Secondary Acute Myeloid Leukemia","Therapy-Related Myelodysplastic Syndrome"],"enrollment":100,"completionDate":"2027-05-31"},{"nctId":"NCT05916339","phase":"PHASE4","title":"AWARE: Management of ADHD in Autism Spectrum Disorder","status":"RECRUITING","sponsor":"Daniel Coury","startDate":"2023-10-01","conditions":["ADHD","Autism Spectrum Disorder"],"enrollment":500,"completionDate":"2027-12-30"},{"nctId":"NCT05618925","phase":"PHASE1","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-08-22","conditions":["Non Hodgkin's Lymphoma Refractory/Relapsed"],"enrollment":20,"completionDate":"2027-03-15"},{"nctId":"NCT02250937","phase":"PHASE2","title":"Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-27","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome"],"enrollment":116,"completionDate":"2027-10-31"},{"nctId":"NCT04734652","phase":"PHASE2","title":"INSTI's For The Management of HIV-associated TB","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2022-02-18","conditions":["HIV/AIDS","Tuberculosis, Pulmonary"],"enrollment":122,"completionDate":"2024-08-31"},{"nctId":"NCT03568968","phase":"PHASE3","title":"A Randomized Controlled Trial of Nicotinamide Riboside Supplementation in Early Parkinson's Disease","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2020-05-06","conditions":["Parkinson Disease"],"enrollment":410,"completionDate":"2025-06-17"},{"nctId":"NCT06971224","phase":"PHASE2","title":"NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals","status":"RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2025-10-13","conditions":["Sleep"],"enrollment":16,"completionDate":"2026-06-01"},{"nctId":"NCT07156435","phase":"PHASE1","title":"Vyxeos® With Clofarabine for Pediatric AML","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2020-11-06","conditions":["Relapsed Pediatric AML","Refractory Pediatric AML"],"enrollment":25,"completionDate":"2028-12-31"},{"nctId":"NCT07085975","phase":"PHASE1","title":"The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-08-05","conditions":["Chronic Cough (CC)","Asthma"],"enrollment":33,"completionDate":"2026-10-01"},{"nctId":"NCT06776510","phase":"PHASE1,PHASE2","title":"A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-15","conditions":["Immune Thrombocytopenia","Treatment"],"enrollment":20,"completionDate":"2026-03-01"},{"nctId":"NCT06491394","phase":"PHASE4","title":"Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats","status":"COMPLETED","sponsor":"Aswan University Hospital","startDate":"2024-11-01","conditions":["Rhabdomyolysis"],"enrollment":24,"completionDate":"2025-04-01"},{"nctId":"NCT07034053","phase":"PHASE1,PHASE2","title":"Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Ekaterina Laukhtina","startDate":"2023-10-24","conditions":["Advanced Urothelial Carcinoma","Metastatic Urothelial Cancer"],"enrollment":50,"completionDate":"2028-11"},{"nctId":"NCT07022834","phase":"PHASE2","title":"Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2025-06-01","conditions":["Langerhans Cell Histiocytosis (LCH)"],"enrollment":20,"completionDate":"2030-06-01"},{"nctId":"NCT03675893","phase":"PHASE2","title":"RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-12-24","conditions":["Endometrial Cancer","Ovarian Cancer"],"enrollment":180,"completionDate":"2031-08-01"},{"nctId":"NCT06986382","phase":"PHASE1,PHASE2","title":"Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2025-07","conditions":["Crohn Disease"],"enrollment":14,"completionDate":"2040-07"},{"nctId":"NCT04264897","phase":"PHASE3","title":"Antecedent Metabolic Health and Metformin Aging Study","status":"COMPLETED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2020-07-29","conditions":["Aging","Insulin Sensitivity","Chronic Disease","Mitochondria","Insulin Resistance"],"enrollment":101,"completionDate":"2025-03-12"},{"nctId":"NCT03304717","phase":"PHASE1,PHASE2","title":"Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-12","conditions":["Aicardi Goutières Syndrome"],"enrollment":0,"completionDate":"2029-12"},{"nctId":"NCT06921720","phase":"NA","title":"Phosphorus-31 Spectroscopy in Phosphate Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-05-01","conditions":["Phosphate Diabetes","X-linked Hypophosphatemia"],"enrollment":65,"completionDate":"2027-05-01"},{"nctId":"NCT06919328","phase":"NA","title":"Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+","status":"RECRUITING","sponsor":"Nutraceuticals Research Institute","startDate":"2024-10-31","conditions":["Healthy Aging"],"enrollment":70,"completionDate":"2025-06-30"},{"nctId":"NCT04500275","phase":"PHASE4","title":"Topical Vancomycin Over Sternal Edge in Cardiac Surgery","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-07-01","conditions":["Sternal Wound Infection"],"enrollment":360,"completionDate":"2025-03-31"},{"nctId":"NCT03615105","phase":"PHASE2","title":"Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-07-25","conditions":["Acute Lymphoid Leukemia (ALL)","Acute Myeloid Leukemia (AML)","Chronic Myeloid Leukemia (CML)","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukemia"],"enrollment":9,"completionDate":"2024-03-06"},{"nctId":"NCT01701986","phase":"PHASE1,PHASE2","title":"Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-25","conditions":["Hematopoietic Cell Transplantation Recipient","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":64,"completionDate":"2024-06-05"},{"nctId":"NCT05200260","phase":"PHASE2","title":"Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer","status":"RECRUITING","sponsor":"Shanghai Gynecologic Oncology Group","startDate":"2022-07-13","conditions":["Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma"],"enrollment":220,"completionDate":"2027-06"},{"nctId":"NCT06806345","phase":"PHASE1,PHASE2","title":"Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-01-28","conditions":["Insulin Resistance Syndrome"],"enrollment":40,"completionDate":"2025-04-28"},{"nctId":"NCT05243108","phase":"NA","title":"Targeting Aging and Promoting Longevity with Exogenous Nucleotides (TALENTs)","status":"COMPLETED","sponsor":"Peking University","startDate":"2022-08-23","conditions":["Aging"],"enrollment":122,"completionDate":"2023-03-29"},{"nctId":"NCT05477589","phase":"PHASE3","title":"Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML","status":"RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2022-06-07","conditions":["Acute Myeloid Leukemia (AML) in Remission","Stem Cell Transplantation"],"enrollment":170,"completionDate":"2031-12-31"},{"nctId":"NCT06558253","phase":"PHASE1","title":"The Safety and Efficacy of Coenzyme I for Injection in Promoting Hematopoietic Recovery of Patients After sUCBT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-11-29","conditions":["Hematopoietic Recovery"],"enrollment":12,"completionDate":"2026-09-30"},{"nctId":"NCT02085408","phase":"PHASE3","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-04","conditions":["Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome","Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Secondary Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia"],"enrollment":727,"completionDate":"2022-12-21"},{"nctId":"NCT01228331","phase":"PHASE2,PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":["Leukemia"],"enrollment":745,"completionDate":"2024-11-20"},{"nctId":"NCT06597357","phase":"","title":"Evaluation of Clinical and Radiographic Outcomes of Meniscal Lesion Treatment Using Collagen Scaffolds (CMI)","status":"COMPLETED","sponsor":"Istituto Ortopedico Rizzoli","startDate":"2020-11-29","conditions":["Meniscal Degeneration","Osteoarthritis of Knee","Meniscus Injury"],"enrollment":60,"completionDate":"2022-11-29"},{"nctId":"NCT04729829","phase":"NA","title":"Fish Consumption and Dietary Diversity in Timor-Leste","status":"COMPLETED","sponsor":"WorldFish","startDate":"2021-05-15","conditions":["Dietary Deficiency"],"enrollment":720,"completionDate":"2022-09-30"},{"nctId":"NCT03722849","phase":"NA","title":"Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients","status":"COMPLETED","sponsor":"Stuart Mazzone","startDate":"2019-03-01","conditions":["Cough"],"enrollment":58,"completionDate":"2022-05-13"},{"nctId":"NCT05569512","phase":"PHASE1","title":"Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML","status":"TERMINATED","sponsor":"Malika Kapadia","startDate":"2022-10-06","conditions":["Acute Myeloid Leukemia","Pediatric Cancer"],"enrollment":1,"completionDate":"2023-12-06"},{"nctId":"NCT04152980","phase":"PHASE3","title":"Pentoxifylline Dose Optimization in Neonatal Sepsis","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2020-01-12","conditions":["Neonatal Late Onset Sepsis"],"enrollment":30,"completionDate":"2022-12-31"},{"nctId":"NCT04336098","phase":"PHASE1","title":"Study of SRF617 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-03-16","conditions":["Advanced Solid Tumor"],"enrollment":85,"completionDate":"2023-08-25"},{"nctId":"NCT06181916","phase":"NA","title":"Quantitative and Qualitative Research for \"mHealth Program to Support People Living With HIV Across the HIV Care Continuum\"","status":"UNKNOWN","sponsor":"Sentient Research","startDate":"2024-04-29","conditions":["HIV Infections"],"enrollment":300,"completionDate":"2024-12-30"},{"nctId":"NCT06382688","phase":"NA","title":"IV Administration of ChromaDex's Niagen® as Compared to NAD+","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nutraceuticals Research Institute","startDate":"2023-11-13","conditions":["Healthy Aging"],"enrollment":53,"completionDate":"2024-08-31"},{"nctId":"NCT00159315","phase":"NA","title":"ATP/AMP Challenge in Healthy Non-smokers, Smokers, Patients With Asthma, and Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2002-10","conditions":["Asthma","COPD","Smoking"],"enrollment":31,"completionDate":"2004-10"},{"nctId":"NCT02135874","phase":"PHASE2","title":"Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-27","conditions":["Acute Bilineal Leukemia","Acute Biphenotypic Leukemia","Acute Leukemia of Ambiguous Lineage","Acute Undifferentiated Leukemia","Mixed Phenotype Acute Leukemia","Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified","Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified","Recurrent Mixed Phenotype Acute Leukemia"],"enrollment":16,"completionDate":"2023-02-21"},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":["Leukemia"],"enrollment":11,"completionDate":"2021-09-22"},{"nctId":"NCT01041508","phase":"PHASE1","title":"Clofarabine and Low Dose Total Body Irradiation as a Preparative Regimen for Stem Cell Transplant in Leukemia.","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-01-29","conditions":["Leukemia Lymphoblastic, Acute","Acute Myeloid Leukemia","Neoplasm Recurrent"],"enrollment":18,"completionDate":"2014-08"},{"nctId":"NCT05573373","phase":"PHASE1","title":"Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of Jiangnan University","startDate":"2022-12-20","conditions":["Carcinoma, Non-Small-Cell Lung","EGF-R Positive Non-Small Cell Lung Cancer"],"enrollment":40,"completionDate":"2025-12-30"},{"nctId":"NCT04220008","phase":"PHASE2","title":"Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-29","conditions":["Recurrent Aggressive Non-Hodgkin Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Burkitt Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent High Grade B-Cell Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Recurrent Transformed B-Cell Non-Hodgkin Lymphoma"],"enrollment":0,"completionDate":"2021-10-29"},{"nctId":"NCT00697684","phase":"PHASE1","title":"Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2008-06","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome","Acute Lymphocytic Leukemia","Relapsed/Refractory Chronic Lymphocytic Leukemia","Relapsed/Refractory Non Hodgkin's Lymphoma","Hodgkins Disease","Relapsed Refractory Multiple Myeloma"],"enrollment":29,"completionDate":"2023-11"},{"nctId":"NCT04989335","phase":"PHASE2","title":"Bisantrene Combination for Resistant AML","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2021-08-02","conditions":["Myelogenous Leukemia, Acute"],"enrollment":29,"completionDate":"2025-12-01"},{"nctId":"NCT05431413","phase":"PHASE2","title":"Rapid Improvement of Depression of Fluoxetine Combined With ATP","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-01-07","conditions":["Depression"],"enrollment":195,"completionDate":"2025-12-30"},{"nctId":"NCT03096782","phase":"PHASE2","title":"Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-13","conditions":["Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Acute Biphenotypic Leukemia","Acute Leukemia","Acute Lymphoblastic Leukemia","Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia","Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","Chemotherapy-Related Leukemia","Chronic Lymphocytic Leukemia","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Hodgkin Lymphoma","Langerhans Cell Histiocytosis","Minimal Residual Disease","Myelodysplastic Syndrome","Myelodysplastic Syndrome With Excess Blasts","Non-Hodgkin Lymphoma","Recurrent Hodgkin Lymphoma","Refractory Acute Lymphoblastic Leukemia","Refractory Myelodysplastic Syndrome","Small Lymphocytic Lymphoma","Therapy-Related Myelodysplastic Syndrome"],"enrollment":6,"completionDate":"2022-09-20"},{"nctId":"NCT06063070","phase":"PHASE2","title":"First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-10-18","conditions":["Ovarian Cancer","High Grade Serous Adenocarcinoma of Ovary","High Grade Endometrioid Ovarian Cancer","Primary Peritoneal Cancer","Fallopian-tube Cancer"],"enrollment":44,"completionDate":"2027-10-30"},{"nctId":"NCT00503880","phase":"PHASE1,PHASE2","title":"Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2007-05-07","conditions":["Myelodysplastic Syndromes"],"enrollment":2,"completionDate":"2009-10-13"},{"nctId":"NCT04002115","phase":"PHASE2","title":"Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML","status":"TERMINATED","sponsor":"Milton S. Hershey Medical Center","startDate":"2020-06-03","conditions":["Acute Myeloid Leukemia"],"enrollment":2,"completionDate":"2022-11-07"},{"nctId":"NCT00641030","phase":"PHASE1","title":"Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-07","conditions":["Leukemia","Myelodysplastic Syndromes"],"enrollment":20,"completionDate":"2011-01"},{"nctId":"NCT05849519","phase":"EARLY_PHASE1","title":"Small Sample，Unicentric，Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss","status":"UNKNOWN","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-02-16","conditions":["Sudden Sensorineural Hearing Loss"],"enrollment":36,"completionDate":"2024-02-16"},{"nctId":"NCT00644189","phase":"PHASE1,PHASE2","title":"Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2008-06","conditions":["Follicular Lymphoma","Marginal Zone Lymphoma","Mantle Cell Lymphoma","Small Lymphocytic Lymphoma","Lymphoplasmacytic Lymphoma","Low Grade B-cell Lymphoma, Not Otherwise Specified","Diffuse Large B-cell Lymphoma","Peripheral T-cell Lymphoma","Angioimmunoblastic T-cell Lymphoma","Anaplastic Large-cell Lymphoma"],"enrollment":50,"completionDate":"2021-07"},{"nctId":"NCT05434533","phase":"PHASE4","title":"The Prophylactic Role of Tranexamic Acid in High Risk Pregnant Women Undergoing Elective Cesarean Section in Prevention of Postpartum Hemorrhage","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-07-03","conditions":["High Risk Pregnant Women Undergoing Elective Cesarean Section"],"enrollment":156,"completionDate":"2023-02-10"},{"nctId":"NCT04604704","phase":"PHASE2","title":"Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome","status":"COMPLETED","sponsor":"AgelessRx","startDate":"2021-01-28","conditions":["Covid19","Long COVID-19","Post-COVID-19 Syndrome"],"enrollment":36,"completionDate":"2023-01-23"},{"nctId":"NCT00423514","phase":"PHASE1,PHASE2","title":"Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-11-20","conditions":["Graft Versus Host Disease","Leukemia","Myelodysplastic Syndromes"],"enrollment":38,"completionDate":"2021-06-18"},{"nctId":"NCT05032729","phase":"NA","title":"Nutritional Intervention to Enhance Sleep Quality and Quantity in Athletes","status":"COMPLETED","sponsor":"PepsiCo Global R&D","startDate":"2022-03-14","conditions":["Sleep","Physical Performance","Cognitive Performance","Balance"],"enrollment":19,"completionDate":"2022-08-09"},{"nctId":"NCT01842672","phase":"PHASE1,PHASE2","title":"Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-03","conditions":["Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Lymphoblastic Lymphoma","Diffuse Large B-cell Lymphoma","Burkitt Lymphoma/Leukemia"],"enrollment":41,"completionDate":"2022-09"},{"nctId":"NCT02686593","phase":"PHASE2","title":"Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-02-01","conditions":["Acute Myeloid Leukemia"],"enrollment":50,"completionDate":"2018-05-01"},{"nctId":"NCT01700946","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-04-15","conditions":["Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia","Recurrent Childhood B-Lymphoblastic Lymphoma"],"enrollment":80,"completionDate":"2021-07-24"},{"nctId":"NCT03186027","phase":"NA","title":"Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2017-06-28","conditions":["Chronic Fatigue Syndrome"],"enrollment":282,"completionDate":"2021-09-01"},{"nctId":"NCT04676204","phase":"","title":"Relationship Between Oral DMT Burden and Adherence in MS","status":"ENROLLING_BY_INVITATION","sponsor":"Monash University","startDate":"2020-09-25","conditions":["Multiple Sclerosis","Adherence, Medication"],"enrollment":323,"completionDate":"2026-07-11"},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":["Acute Lymphoblastic Leukemia"],"enrollment":600,"completionDate":"2022-03-26"},{"nctId":"NCT00198991","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-04","conditions":["Adult Acute Lymphocytic Leukemia"],"enrollment":1883,"completionDate":"2013-06-30"},{"nctId":"NCT01119066","phase":"PHASE2","title":"HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2010-05-03","conditions":["Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Myelodysplastic Syndrome","Multiple Myeloma"],"enrollment":422,"completionDate":"2021-03-30"},{"nctId":"NCT03263767","phase":"PHASE2","title":"Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC","status":"TERMINATED","sponsor":"Nantes University Hospital","startDate":"2018-01-15","conditions":["Graft Versus Host Disease"],"enrollment":47,"completionDate":"2022-06-21"},{"nctId":"NCT03690544","phase":"PHASE4","title":"Apremilast for RAS","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-10-12","conditions":["Recurrent Aphthous Stomatitis"],"enrollment":15,"completionDate":"2021-07-14"},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":["Lymphoblastic Lymphoma"],"enrollment":23,"completionDate":"2022-05-31"},{"nctId":"NCT01306994","phase":"","title":"Study of Resting and Exercising Body Functioning in Freeman-Sheldon Syndrome and Related Conditions","status":"WITHDRAWN","sponsor":"Freeman-Sheldon Research Group, Inc.","startDate":"2014-03","conditions":["Arthrogryposis","Craniofacial Abnormalities"],"enrollment":0,"completionDate":"2022-06"},{"nctId":"NCT00042341","phase":"PHASE2","title":"Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2002-05","conditions":["Leukemia, Lymphoblastic, Acute, Pediatric"],"enrollment":60,"completionDate":"2006-01"},{"nctId":"NCT00416351","phase":"PHASE1,PHASE2","title":"Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2006-06-27","conditions":["Leukemia","Lymphoma","Small Intestine Cancer"],"enrollment":29,"completionDate":"2021-03-01"},{"nctId":"NCT03802097","phase":"NA","title":"Study About no Antimicrobial Prophylaxis in Totally Laparoscopic Distal Gastrectomy","status":"COMPLETED","sponsor":"Korean South West East Gastric Surgery Group","startDate":"2018-12-27","conditions":["Gastric Cancer","Complication of Surgical Procedure"],"enrollment":260,"completionDate":"2022-03-25"},{"nctId":"NCT00531232","phase":"PHASE2","title":"A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2007-05-07","conditions":["Myelodysplastic Syndromes","Secondary Acute Myeloid Leukemia (AML)"],"enrollment":38,"completionDate":"2011-05-12"},{"nctId":"NCT03519217","phase":"","title":"Genetic Study for Infantile Onset Diabetes Mellitus","status":"UNKNOWN","sponsor":"Shimaa Kamal","startDate":"2020-06-05","conditions":["Gene Mutation in Infantile Onset Diabetes Mellitus"],"enrollment":60,"completionDate":"2022-12"},{"nctId":"NCT02083250","phase":"PHASE1","title":"Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-03-06","conditions":["Acute Lymphoblastic Leukemia in Remission","Acute Myeloid Leukemia in Remission","Allogeneic Hematopoietic Stem Cell Transplantation Recipient","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Acute Lymphoblastic Leukemia","Recurrent Acute Myeloid Leukemia"],"enrollment":70,"completionDate":"2021-11-12"},{"nctId":"NCT01471444","phase":"PHASE3","title":"Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-02","conditions":["Disorder Related to Bone Marrow Transplantation","Leukemia","Transplantation Infection"],"enrollment":256,"completionDate":"2020-12-14"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000170817","MMSL":"1085","NDDF":"002392","UNII":"415SHH325A","VUID":"4018975","CHEBI":"CHEBI:16027","VANDF":"4018975","INN_ID":"335","RXNORM":"296","UMLSCUI":"C0001465","chemblId":"CHEMBL1775011","ChEMBL_ID":"CHEMBL752","KEGG_DRUG":"D02769","DRUGBANK_ID":"DB00131","PDB_CHEM_ID":" A  ","PUBCHEM_CID":"6083","SNOMEDCT_US":"108502004","IUPHAR_LIGAND_ID":"2455","MESH_DESCRIPTOR_UI":"D000249"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":203,"therapeuticAreas":["Respiratory"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 10","pmid":"41723807","title":"Chemoproteomic Profiling of ATP-Binding Sites with Acid-Cleavable Photoreactive Adenosine Phosphate Probes.","journal":"Analytical chemistry"},{"date":"2025 Dec 1","pmid":"41332405","title":"[Correlation analysis of cell-free DNA in gingival crevicular fluid with periodontal clinical indicators and cyclic guanosine phosphate-adenosine phosphate synthase-stimulator of interferon genes signaling pathway].","journal":"Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology"},{"date":"2025 Sep-Oct","pmid":"40998586","title":"Shoot Nitrate Status Regulates Arabidopsis Shoot Growth and Systemic Transcriptional Responses via Shoot Adenosine Phosphate-Isopentenyltransferase 3.","journal":"Physiologia plantarum"},{"date":"2006","pmid":"40864838","title":"Lumasiran.","journal":""},{"date":"2025 Oct","pmid":"40808650","title":"Sexual Dimorphism of Plasma and Tissue Proteomes in Human Calcific Aortic Valve Stenosis Pathogenesis-Brief Report.","journal":"Arteriosclerosis, thrombosis, and vascular biology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-19T23:19:57.914670+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}